Which class of anti-cancer drugs does Sorafenib belong to?
Sorafenibis a diaryl urea and an oral multi-kinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases related to tumor cell proliferation and tumor angiogenesis. Sorafenibis used to treat unresectable liver cancer, advanced renal cancer and differentiated thyroid cancer.

During early sorafenib treatment, the tumors gradually shrank. Before targeted therapy, the tumor size was 7.7cm× 7.9cm× 6.3cm. On the 5th week of targeted therapy, the tumor size decreased by 39.8%. On the 15 week of targeted therapy, the tumor size was reduced by 96.9%. According to an analysis of the SEER-Medicare database by Parikh and colleagues, patients treated with sorafenib had a median survival of 150.5 days compared with 62 days in the control group. The effect of sorafenib is relatively optimistic.
Sorafenib is a tablet that is usually taken twice daily with a glass of water. The patientshould accept no or only low-fat foods. High-fat foods may make sorafenib less effective. If the patient wants to eat high-fat food, take it at least 1 hour before or 2 hours after the meal. Sorafenib is an oral TKI that targets tumor angiogenesis and proliferation pathways by blocking vascular endothelial growth factor receptor (VEGFR)1–3
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)